These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 8087305)

  • 21. Molecular characterization of post-transplant lymphoproliferative disorders of donor origin occurring in liver transplant recipients.
    Capello D; Rasi S; Oreste P; Veronese S; Cerri M; Ravelli E; Rossi D; Minola E; Colosimo A; Gambacorta M; Muti G; Morra E; Gaidano G
    J Pathol; 2009 Aug; 218(4):478-86. PubMed ID: 19391128
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus.
    Hanto DW; Frizzera G; Purtilo DT; Sakamoto K; Sullivan JL; Saemundsen AK; Klein G; Simmons RL; Najarian JS
    Cancer Res; 1981 Nov; 41(11 Pt 1):4253-61. PubMed ID: 6272971
    [TBL] [Abstract][Full Text] [Related]  

  • 23. EBV-induced post-transplant lymphoproliferative disorder (PTLD).
    Birkeland SA; Hamilton-Dutoit S; Sandvej K; Andersen HM; Bendtzen K; Møller B; Jørgensen KA
    Transplant Proc; 1995 Dec; 27(6):3467-72. PubMed ID: 8540055
    [No Abstract]   [Full Text] [Related]  

  • 24. Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.
    Young L; Alfieri C; Hennessy K; Evans H; O'Hara C; Anderson KC; Ritz J; Shapiro RS; Rickinson A; Kieff E
    N Engl J Med; 1989 Oct; 321(16):1080-5. PubMed ID: 2552313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphoma resembling Hodgkin disease after posttransplant lymphoproliferative disorder in a liver transplant recipient.
    Nalesnik MA; Randhawa P; Demetris AJ; Casavilla A; Fung JJ; Locker J
    Cancer; 1993 Nov; 72(9):2568-73. PubMed ID: 8402478
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epstein-Barr virus PCR correlated with viral histology and serology in pediatric liver transplant patients.
    Rogers BB; Conlin C; Timmons CF; Dawson DB; Krisher K; Andrews WS
    Pediatr Pathol Lab Med; 1997; 17(3):391-400. PubMed ID: 9185219
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prevention and preemptive therapy of postransplant lymphoproliferative disease in pediatric liver recipients.
    McDiarmid SV; Jordan S; Kim GS; Toyoda M; Goss JA; Vargas JH; Martín MG; Bahar R; Maxfield AL; Ament ME; Busuttil RW
    Transplantation; 1998 Dec; 66(12):1604-11. PubMed ID: 9884246
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bone marrow transplantation for Epstein-Barr virus-related clonal T cell proliferation associated with hemophagocytosis.
    Imashuku S; Naya M; Yamori M; Nakabayashi Y; Hojo M; Kihara A; Tabata Y; Akioka C; Hibi S; Todo S
    Bone Marrow Transplant; 1997 May; 19(10):1059-60. PubMed ID: 9169655
    [No Abstract]   [Full Text] [Related]  

  • 29. Posttransplant lymphoproliferative disease in primary Epstein-Barr virus infection after liver transplantation: the role of cytomegalovirus disease.
    Mañez R; Breinig MC; Linden P; Wilson J; Torre-Cisneros J; Kusne S; Dummer S; Ho M
    J Infect Dis; 1997 Dec; 176(6):1462-7. PubMed ID: 9395355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Post-transplant lymphoproliferative disorders. Molecular analysis of histogenesis and pathogenesis.
    Capello D; Berra E; Cerri M; Gaidano G
    Minerva Med; 2004 Feb; 95(1):53-64. PubMed ID: 15041926
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Establishment of Epstein-Barr virus-associated lymphoma cell line SUBL with t(2;3)(p11;q27) from a liver transplant patient.
    Yoshizawa K; Kiyosawa K; Yamada S; Furuta K; Yabu K; Kitano K; Akamatsu T; Nakayama J; Katsuyama T; Matsunami H
    Cancer Genet Cytogenet; 1993 Dec; 71(2):155-63. PubMed ID: 7506636
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epstein--Barr virus post-transplant lymphoproliferative disease and virus-specific therapy: pharmacological re-activation of viral target genes with arginine butyrate.
    Mentzer SJ; Perrine SP; Faller DV
    Transpl Infect Dis; 2001 Sep; 3(3):177-85. PubMed ID: 11493400
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Significance of Epstein-Barr virus status and post-transplant lymphoproliferative disease in pediatric thoracic transplantation.
    Harwood JS; Gould FK; McMaster A; Hamilton JR; Corris PA; Hasan A; Gennery AR; Dark JH
    Pediatr Transplant; 1999 May; 3(2):100-3. PubMed ID: 10389130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epstein-Barr virus polymerase chain reaction and serology in pediatric post-transplant lymphoproliferative disorder: three-year experience.
    Rogers BB; Sommerauer J; Quan A; Timmons CF; Dawson DB; Scheuermann RH; Krisher K; Atkins C
    Pediatr Dev Pathol; 1998; 1(6):480-6. PubMed ID: 9724334
    [TBL] [Abstract][Full Text] [Related]  

  • 35. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation.
    Cox KL; Lawrence-Miyasaki LS; Garcia-Kennedy R; Lennette ET; Martinez OM; Krams SM; Berquist WE; So SK; Esquivel CO
    Transplantation; 1995 Feb; 59(4):524-9. PubMed ID: 7533344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus-related localized hepatic lymphoproliferative disorders after liver transplantation.
    Raymond E; Tricottet V; Samuel D; Reynès M; Bismuth H; Misset JL
    Cancer; 1995 Oct; 76(8):1344-51. PubMed ID: 8620407
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early gene expression changes by Epstein-Barr virus infection of B-cells indicate CDKs and survivin as therapeutic targets for post-transplant lymphoproliferative diseases.
    Bernasconi M; Ueda S; Krukowski P; Bornhauser BC; Ladell K; Dorner M; Sigrist JA; Campidelli C; Aslandogmus R; Alessi D; Berger C; Pileri SA; Speck RF; Nadal D
    Int J Cancer; 2013 Nov; 133(10):2341-50. PubMed ID: 23640782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of methylation in the phenotype-dependent modulation of Epstein-Barr nuclear antigen 2 and latent membrane protein genes in cells latently infected with Epstein-Barr virus.
    Ernberg I; Falk K; Minarovits J; Busson P; Tursz T; Masucci MG; Klein G
    J Gen Virol; 1989 Nov; 70 ( Pt 11)():2989-3002. PubMed ID: 2479717
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease.
    Tanner JE; Alfieri C
    Leuk Lymphoma; 1996 May; 21(5-6):379-90. PubMed ID: 9172802
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological study of severe chronic active Epstein-Barr virus infection that developed in association with lymphoproliferative disorder and/or hemophagocytic syndrome.
    Ohshima K; Suzumiya J; Sugihara M; Nagafuchi S; Ohga S; Kikuchi M
    Pathol Int; 1998 Dec; 48(12):934-43. PubMed ID: 9952337
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.